Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...

Recursion Pharmaceuticals laid off under 20% of staff following merger with Exscientia. Oxford Nanopore partners with UK Biobank for epigenetic dataset project. Portage Biotech continues strategic ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Idor­sia is mak­ing moves to stretch its cash re­serves fur­ther. The Swiss drug­mak­er said it is nar­row­ing its ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

The Biden ad­min­is­tra­tion pro­posed a new rule Tues­day that would ex­pand Medicare and Med­ic­aid cov­er­age of pop­u­lar ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...